Navigation Links
Drug Controller General to Withdraw Drug that Affects Vulture Population

Concerned at the effect of the anti-inflammatory drug Dicolofenec on the country's vulture population, the Drug Controller General has decided to withdraw licences for manufacturing it for veterinary use //.

At a press meet here today, the director of the prominent NGO Bombay Natural History Society (BNHS), Asad R Rahmani, presented a copy of Drug Controller General Ashwini Kumar's May 11 circular to all state drugs controllers to this effect.

The circular said with the approval of the Health Mministry, the licences granted for making Diclofenec for veterinary use should be withdrawn and the marketing of such formulations phased out within a period of three months.

Stating that serious concern had been expressed over the decline of the vulture population, the circular said extensive studies had indicated the use of Diclofenec among livestock was a major cause for this.

Expressing concern at the fall in the vulture population, Rahmani said his organisation had been urging the Centre to ban the drug for veterinary use.

Vultures are exposed to Diclofenec when they eat the carcasses of livestock treated with the drug before death, resulting in poisoning of the birds and their death because of kidney failure, the circular said.

It was, therefore, felt Diclofenec for veterinary use should be phased out and alternate safer and effective drugs like Meloxicam should be used for treating animals in veterinary healthcare.

This will help in saving the vulture population and the ecological balance in the animal world, Kumar said.


'"/>




Page: 1

Related medicine news :

1. Bypass Heart Surgery Performed Without General Anesthesia
2. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
3. General Anesthesia For Heroin Detoxification Is No Good
4. General Practitioners are earning mighty amount?
5. Former IMO President Shows Interest In Winning General Election
6. Severe Paucity of General Practitioners in Australia
7. WHO Director-General passes away on 23rd of May
8. IT for General Practitioners
9. Fewer Graduates Choosing General Practice
10. Stroke Rehab Programs Should Be Generalized
11. China Nominates Margaret Chan to Run for WHO Director-Generals Post
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... Guide to ... , No matter on which side of the Atlantic devicemakers do business, ... regulations they have to follow. , In addition to the full text of the ...
(Date:6/28/2017)... ... June 28, 2017 , ... Anyone with a remote control has seen the never-ending twists ... you the flipper will get rich in no time. But what about the buyers ... get for the buyer of a flipped house. An email recently sent to Gary ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... David B. Sosin, a founding ... Illinois, took over the post of 2nd Vice President for the Illinois State Bar ... installed as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served ...
(Date:6/28/2017)... ... ... American Farmer proudly announces the participation of Pure Line Seeds, Inc (Pure ... broadcast fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , Founded ... As demand grew, the small company located in Moscow, Idaho extended its sales from ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... ZEON) is pleased to announce that a two year study conducted by the ... Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... CALABASAS, Calif. , June 14, 2017 ... with the City of Fremont ... chain of the bio-pharma industry in California ... sharing technology, enabling executive networking, and fostering workforce development. ... the development and growth of start-ups, as well as ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company (NYSE: ... three Phase 3 studies of galcanezumab, an investigational treatment ... late-breaking data on several key secondary endpoints for galcanezumab ... from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be ... scientific meeting in Boston . ...
(Date:6/8/2017)... MAITLAND, Fla. , June 8, 2017  Less ... ransomware attack that hit more than 200,000 companies, including hospital ... is being heralded as one of the largest online ... technology in the healthcare market, it is imperative that ... can protect their data from this — and many ...
Breaking Medicine Technology: